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Purpose: Conventional MRI based on contrast enhancement is often not sufﬁcient in differentiating grade II from
grade III and grade III from grade IV diffuse gliomas. We assessed advanced MRI, MR spectroscopy and [18F]-
ﬂuoro-L-thymidine ([18F]-FLT) PET as tools to overcome these limitations.
Methods: In this prospective study, thirty-nine patients with diffuse gliomas of grades II, III or IV underwent con-
ventionalMRI, perfusion, diffusion, protonMR spectroscopy (1H-MRS) and [18F]-FLT-PET imaging before surgery.
Relative cerebral blood volume (rCBV), apparent diffusion coefﬁcient (ADC), Cho/Cr, NAA/Cr, Cho/NAA and FLT-
SUV were compared between grades.
Results: Cho/Cr showed signiﬁcant differences between grade II and grade III gliomas (p=0.03). To discriminate
grade II from grade IV and grade III from grade IV gliomas, themost relevant parameterwas themaximum value
of [18F]-FLT uptake FLTmax (respectively, p b 0.001 and p b 0.0001). The parameter showing the best correlation
with the grade was the mean value of [18F]-FLT uptake FLTmean (R
2 = 0.36, p b 0.0001) and FLTmax (R
2 = 0.5,
p b 0.0001).
Conclusion:Whereas advanced MRI parameters give indications for the grading of gliomas, the addition of [18F]-
FLT-PET could be of interest for the accurate preoperative classiﬁcation of diffuse gliomas, particularly for identi-
ﬁcation of doubtful grade III and IV gliomas.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diffuse gliomas are the most common primary brain tumors in
adults and encompass a heterogeneous group of tumors with different
histopathological features, aggressiveness, imaging, response to treat-
ment and survival.
They are primarily deﬁned by the histopathological tumor tissue
analysis and subdivided by the World Health Organization (WHO)F-14033, France. Tel.: +33 2 31
).
. This is an open access article underclassiﬁcation into grade II (low grade glioma), grade III (anaplastic
glioma) and grade IV (glioblastoma multiforme, GBM).
Accurate distinction between different grades is of signiﬁcant clinical
importance because of its strong prognostic and treatment decision-
making implications (Louis et al., 2007). However, histopathological
criteria of the grading system present some limitations such as the lack
of reproducibility and the prognostic heterogeneity within the same
group (Ricard et al., 2012). To improve this classiﬁcation, somemolecular
markers not only have diagnostic and prognostic implications, but also
therapeutic efﬁcacy prediction (1p/19q co-deletion, IDH1/IDH2 muta-
tions and MGMT promoter methylation) (Riemenschneider et al.,
2010). However, these approaches require a resection or a biopsy andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2010). Furthermore, there is a need to identify criteria of aggressiveness
for inoperable patients.
MRI is a part of the daily management of the patients by providing
anatomical and vascular information. The presence or the absence
of T1 enhancement after gadolinium-chelate injection, necrosis, mass
effect and surrounding tumor edema are established parameters
used in characterizing tumor aggressiveness (Dean et al., 1990). The
presence of contrast enhancement in diffuse glioma, related to the per-
meability of the blood–brain-barrier (BBB) reﬂecting neovasculariza-
tion, is often regarded as a sign of malignancy. However, it presents
some limitations and does not allow for reliable separation between dif-
ferent grades. For example, although the absence of contrast enhance-
ment is a commonly used criterion for identifying grade II gliomas, it
does not eliminate formally a malignant tumor (Ginsberg et al., 1998;
Scott et al., 2002). In contrast, the presence of contrast enhancement
and even necrosis, characteristic of GBM, can be observed in pure
grade III oligodendrogliomas.
In this context, multimodal imaging based on MRI and PET parame-
ters, by assessing tumor pathophysiology such asmicrovasculature,me-
tabolism, proliferation or cellularity, could be of additional value.
Previous reports have described and compared the performance of
glioma grading using advancedMRI techniques such as relative cerebral
blood volume (rCBV), apparent diffusion coefﬁcient (ADC), and metab-
olites of Magnetic Resonance Spectroscopy (MRS) (Arvinda et al., 2009;
Hilario et al., 2012; Law et al., 2003; van den Bent, 2010; Yang et al.,
2002; Zonari et al., 2007; Zou et al., 2011). Others focus speciﬁcally on
glioma grading with the thymidine analog [18F]-ﬂuoro-L-thymidine
([18F]-FLT), developed as a positron emission tomography (PET) tracer
to assess the proliferation activity of tumors in vivo, particularly in
brain tumors (Chalkidou et al., 2012; Chen et al., 2005; Hatakeyama
et al., 2008; Jacobs et al., 2005). Even if these multimodal imaging pa-
rameters are useful to distinguish grade II from higher grades (anaplas-
tic and GBM), the differentiating criteria of grade III from grade IV
gliomas, two groups with different prognoses and management, are
still poorly deﬁned.
The aim of this study was to compare the performance of these ad-
vanced MR techniques, namely perfusion, diffusion and proton MR
spectroscopy (1H-MRS) with that of [18F]-FLT-PET, by pre-operatively
assessing the diagnostic accuracy of each parameter in differentiating
glioma grades.2. Methods
2.1. Patients
This study was based on a prospective clinical trial funded by
INCa (Institut National du Cancer) and approved by the local ethics
committee and AFSSAPS agreement (ClinicalTrials.gov identiﬁer:
NCT00850278). Forty patients were included in the Caen University
Hospital. Inclusion criteria were: a presumed diffuse glioma amenable
to surgical resection or biopsy, age greater than or equal to 18, KPS
greater than or equal to 50, normal blood cell count, normal biological
hepatic functions and a signed informed consent. The group sizes of
the different tumor grades were the result of the incidence of each
tumor in this prospective study. Patients ﬁrst underwent [18F]-FLT-
PET, followed by multiparametric MRI/MRS within the same week and
prior to surgery. Single voxel MRS was localized in the area with maxi-
mum visible uptake of [18F]-FLT. Thereafter, patients underwent sur-
gery, resection or biopsy depending on the location of the tumor, and
the specimens were histopathologically evaluated by an experienced
neuropathologist (ELZ). Majority of patients had image-guided total or
subtotal surgical resection (Table 1). For patients with biopsy only, the
biopsy was guided by the area with maximum visible uptake of [18F]-
FLT. For grade III tumors or for difﬁcult cases, the diagnosis and gradingwere reviewed by the national multicentric network “Prise en charge
des OLigodendrogliomes Anaplasiques POLA” (Idbaih et al., 2012).
2.2. Image acquisition
MR imagingwas performed on a 1.5 Tesla GEMS version HDXt 15.0.
After scout-view and coronal T2-weighted imaging, an axial FLAIR
(Fluid Attenuated Inversion Recovery) sequence was performed (24
slices, slice spacing 5.5, pixel resolution 0.47 × 0.47 mm, TR/TE = 9602/
150 ms). Diffusion Weighted Imaging (DWI) was performed using
Spin-Echo-Echo Planar Imaging (SE-EPI) (3 diffusion directions, 36 slices,
slice spacing: 7 mm, pixel resolution: 1.09 × 1.09 mm, TR/TE = 6000/
96ms, b≈0 andb≈1000 s•mm2). For perfusion, dynamic T2*-weighted
EPI images were acquired 30 s before, during the ﬁrst pass of Gd-
DOTA (Dotarem®, Guerbet, France) and 1 min after with a standard
0.1 mmol/kg body weight dose (14 slices, 35 repetitions, slice spacing:
7 mm, pixel resolution 2.19 × 2.19 mm, TR/TE = 2280/60 ms). Immedi-
ately thereafter, a 3DT1-weighted sequence, 3DT1w-Gd (124 slices, slice
spacing 1.5, pixel resolution 1.01 × 1.01mm, TR/TE= 17/3ms)was per-
formed to evaluate the tumor contrast enhancement. Finally, MRS data
were acquired in a single voxel (1 cm3) localized in the tumor in the
area of maximal uptake of FLT and in the normal-appearing contralateral
side with PRESS MRS sequence with multiple TE (35, 144, 288 ms) and
water suppression.
FLT-PET [18F]-FLT was produced by the LDM-TEP group and synthe-
sized at the CYCERON TEP center as previously described by Jacobs
et al. (2005). Acquisitionswere performed on a General Electric Discov-
ery VCT 64 PET scanner. Images of the brain were acquired 40min after
the intravenous injection of 5 MBq/kg of 18F-FLT and lasted 10 min, to
match a clinically feasible approach. The attenuation-corrected images
were reconstructed with an OSEM 2D algorithm (9 subsets and 2 itera-
tions) and ﬁltered in 3D with a Butterworth ﬁlter.
2.3. Image analysis
ADC maps were computed from DWI. The ADC (apparent diffusion
coefﬁcient) maps were calculated pixel-by-pixel using ImageJ software
(http://rsb.info.nih.gov/ij/, 1997–2012) using the following equation:
ADC =−[ln(S/S0)]/b where S is the signal (averaged over the 3 direc-
tions) acquired, b = 1000, and S0 = the signal acquired without diffu-
sion gradient. Values were expressed as 10−6 mm2/s. rCBV maps were
computed using perfusion imaging. Variations of the T2* signal in the
tissue, which is proportional to the concentration of the contrast
agent, were calculated with in-house macros based on ImageJ software
as: ΔR2*(t) =−ln(S(t)/S0), where S0 = the signal intensity before con-
trast agent injection, and S(t) = the signal intensity over time. Then,
CBV maps were generated by integrating the area under the γ-variate
ﬁtted curves to avoid an effect of recirculation. Images were then nor-
malized by dividing CBV maps with the mean value of the normal-
appearing contralateral side. Coregistration: ADC maps, rCBV maps,
FLAIR and PET-FLT images were coregistered with trilinear interpola-
tion, rigid matching and normalized mutual information on 3DT1w-
Gd images (PMOD 3.1® software).
2.4. ROI segmentation
Thehypersignal in FLAIR imageswasmanually delineated todeﬁne a
Region Of Interest (ROI) in order to use a homogeneous method to de-
ﬁne a pathological area (tumor, peripheral edema and inﬁltration
areas) for the different grades, despite the presence or absence of T1 en-
hancement. When present, necrosis was excluded.
2.5. Parameter extraction
Tumor ROIs were reported for each modality (rCBV, ADC, T1 en-
hancement, FLT-PET) to extract the mean value for each modality, the
Table 1
Patients and tumor characteristics (GGII: glioma grade II, GGIII: glioma grade III, GGIV: glioma grade IV, M: male, F: female, R: right, L: left, CC: corpus callosum, CE: contrast enhancement
after gadolinium injection, nec: necrosis, Yes: 1, No: 0, EOR: extent of resection, PE: partial resection, CR: complete resection, B: biopsy, NA: not available).
Patient Sex Age KPS Tumor location CE Nec EOR WHO grade Pathological diagnosis
1 F 55 100 Frontal, L 0 0 PR 2 Oligodendroglioma
2 M 62 NA Temporal, R 0 0 CR 2 Oligodendroglioma
3 F 53 100 Temporal, L 0 0 CR 2 Oligodendroglioma
4 F 60 NA Frontal, R 0 0 CR 2 Oligodendroglioma
5 M 38 100 Frontal, L 0 0 PR 2 Oligodendroglioma
6 F 44 100 Parietal, temporal, R 0 0 PR 2 Oligodendroglioma
7 F 27 100 Central 0 0 PR 2 Oligodendroglioma
8 F 60 90 CC 1 0 CR 3 Oligodendroglioma
9 F 41 90 Frontal, R 1 0 CR 3 Oligodendroglioma
10 F 29 100 Parietal, L 0 0 CR 3 Oligoastrocytoma
11 F 25 100 Frontal, L 0 0 CR 3 Oligoastrocytoma
12 F 48 NA Frontal, L 0 0 CR 3 Oligodendroglioma
13 M 47 80 Temporal, insular, R 1 0 B 3 Oligodendroglioma
14 F 46 90 Frontal, L 0 0 CR 3 Oligodendroglioma
15 M 50 90 frontal, temporal, insular, L 1 1 PR 3 Astrocytoma
16 F 38 100 Temporal, R 1 1 CR 3 Oligodendroglioma
17 M 58 80 Parietal, occipital, R 1 1 PR 4 Glioblastoma
18 F 74 80 Parietal, temporal, occipital, L 1 1 CR 4 Glioblastoma
19 M 73 80 Frontal, parietal, temporal, R 1 1 CR 4 Glioblastoma
20 M 59 80 Frontal, R 1 0 CR 4 Glioblastoma
21 M 70 100 Parietal, central, L 1 1 CR 4 Glioblastoma
22 F 44 70 Frontal, bilateral, multifocal 1 1 B 4 Glioblastoma
23 F 46 80 Frontal, CC, L 1 1 PR 4 Glioblastoma
24 M 52 80 Parietal, L 1 1 CR 4 Glioblastoma
25 F 70 80 Frontal, occipital, multifocal 1 1 B 4 Glioblastoma
26 M 24 100 Frontal, temporal 1 1 CR 4 Glioblastoma
27 M 52 80 Frontal, R 1 1 CR 4 Glioblastoma
28 F 64 80 Frontal, parietal, CC, multifocal, L 1 1 B 4 Glioblastoma
29 M 28 100 Parietal, temporal, insular, L 1 1 PR 4 Glioblastoma
30 M 58 90 temporal, R 1 1 CR 4 Glioblastoma
31 M 79 80 Frontal, bilateral 1 1 B 4 Glioblastoma
32 M 67 80 Occipital 1 1 B 4 Glioblastoma
33 M 53 70 Frontal, multifocal 1 1 B 4 Glioblastoma
34 M 64 80 Frontal, L 1 1 CR 4 Glioblastoma
35 M 52 80 Frontal, R 1 1 PR 4 Glioblastoma
36 M 74 80 Frontal, parietal, L 1 1 CR 4 Glioblastoma
37 M 72 60 Frontal, CC, bilateral, multifocal 1 1 B 4 Glioblastoma
38 M 62 80 Occipital, CC, L 1 1 PR 4 Glioblastoma
39 M 67 90 Temporal, insular, R 1 1 B 4 Glioblastoma
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ADC. To avoid sensitivity to extreme values, the minimum value was
associated with the 10th percentile (p10) and the maximum value
with the 90th percentile (p90). In MRS, choline (Cho), creatine (Cr),
N-Acethyl-Aspartate (NAA), phospholipids and lactate were quantiﬁed
with SA/GE software (GE) to obtain peak amplitudes and areas (propor-
tional to concentration and relaxation) from spectra with water reso-
nance suppression, and expressed as a ratio.
2.6. Statistical analysis
Statistical analyses were performed with JMP© software. Analysis
was performed between all grades. p-Values of comparisons between
grades were calculated using the non-parametric Wilcoxon test. A p-
value b 0.05 was considered statistically signiﬁcant. Ordinal logistic re-
gression was used to assess the degree of correlation (R2) of each pa-
rameter with the grade. Only R2 values with p-value b 0.05 were
considered signiﬁcant.
3. Results
3.1. Patients and tumor characteristics
Among the 40 patients included in the study, 1 had an incomplete
MRI examination. Of the 39 remaining patients, all presentedhistopathologically proven diffuse glioma based on WHO criteria and
were eligible in the ﬁnal analysis (ranging from 21 to 79 years old, 17
women and 22 men). The diagnosis was established from biopsy spec-
imens (n = 9) or from resection (10 patients with a partial resection
and 20 patients with a macroscopically complete resection) yielding 7
patients with grade II glioma, 9 patients with grade III glioma and 23 pa-
tients with grade IV glioma. Table 1 shows patients and tumor
characteristics.3.2. Interest of multimodal imaging at the individual level
Fig. 1 illustrates the multimodal imaging of tumors of each grade.
Grade II gliomas typically looked like a non-enhancing lesion that had
no modiﬁcation on CBV maps and no [18F]-FLT uptake (Fig. 1). Most
grade III gliomas showed a slightly enhancing lesion with mild [18F]-
FLT uptake (Fig. 1: Grade III (a)). In contrast, grade IV gliomas typically
exhibited a strong contrast enhancement, elevated rCBV, and high [18F]-
FLT uptake (Fig. 1: Grade IV (a)). Interestingly, some grade III glioma
presented a proﬁle indicative of a GBM, i.e. sustained contrast enhance-
ment, strong modiﬁcation in ADC, elevated Cho/Cr and rCBV, appear-
ance of lipids/lactate but [18F]-FLT clearly demonstrated a weak tumor
cell proliferation (Fig. 1: Grade III (b)).
On the opposite, a grade IV glioma presented non-objectivablemod-
iﬁcation in perfusion but an intense [18F]-FLT uptake favoring the diag-
nosis of a GBM instead of a grade III glioma (Fig. 1: Grade IV (b)).
Fig. 1.Multimodal aspect on imaging of a patient with a grade II glioma, two patients with a grade III glioma and two patients with a grade IV glioma.
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Between grade II and grade IV gliomas rCBVmean, rCBVmax, FLTmean,
FLTmax, CEmean, CEmax, Cho/Cr and Cho/NAA showed signiﬁcantTable 2
Quantiﬁcation of imaging parameters for grade II gliomas (n=7), grade III gliomas (n=9) an
from a logistic regression analysis between the grade and the parameters (NS: not signiﬁcant)
Grade II (mean ± SD) Grade III (mean ± SD) G
ADCmean (10−6 mm2/s) 1201 ± 89 1345 ± 130 1
ADCmin (10−6 mm2/s) 903 ± 66 962 ± 55
rCBVmean 1.18 ± 0.19 1.11 ± 0.35 1
rCBVmax 1.88 ± 0.37 1.77 ± 0.52 2
Cho/Cr 1.41 ± 0.20 3.71 ± 4.04 3
NAA/Cr 1.15 ± 0.28 0.85 ± 0.40 0
Cho/NAA 1.18 ± 0.41 4.91 ± 4.66 3
FLTmean (g/ml) 0.27 ± 0.09 0.25 ± 0.09 0
FLTmax (g/ml) 0.34 ± 0.09 0.33 ± 0.14 1differences (Table 2). The most relevant parameter was FLTmax
(p b 0.001) (Fig. 2, Table 2).
Between grade III and grade IV gliomas, ADCmean, ADCmin, rCBVmean,
rCBVmax, FLTmean, FLTmax, CEmean, and CEmax showed signiﬁcantd grade IV (n=23). p-Values from theWilcoxon test, values of R2 with signiﬁcant p-value
.
rade IV (mean ± SD) Wilcoxon test (p-value) Logistic regression
II/III III/IV II/IV R2 p-Value
176 ± 129 NS 0.013 NS 0.04 NS
837 ± 71 NS b0.001 NS 0.15 b0.01
.59 ± 0.43 NS 0.010 0.035 0.15 b0.01
.73 ± 0.68 NS b0.01 0.013 0.21 b0.001
.65 ± 1.97 0.03 NS b0.01 0.03 NS
.89 ± 0.33 NS NS NS 0.01 NS
.84 ± 2.44 NS NS 0.021 0.01 NS
.61 ± 0.23 NS b0.001 b0.01 0.36 b0.0001
.27 ± 0.56 NS b0.0001 b0.001 0.5 b0.0001
Fig 2. Graphic representation of the parameters used to distinguish between grade II gliomas (n= 7), grade III gliomas (n= 9) and grade IV gliomas (n= 23).
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(p b 0.0001) (Fig. 2, Table 2). Cho/Cr showed signiﬁcant differences be-
tween grade II and grade III gliomas (p= 0.03).
The parameter showing the best signiﬁcant correlation with the
grade was FLTmax (R2 = 0.5, p b 0.0001) (Table 2).
4. Discussion
The prognosis and management of patients with diffuse glioma are
strongly dependent on the accurate grading of the tumor. MRI plays a
crucial role in the assessment of aggressiveness of gliomas before sur-
gery but may remain insufﬁcient to forecast prognosis of diffuse glio-
mas. Therefore, multimodal imaging parameters with advanced MRI
(CBV and ADC), MRS and [18F]-FLT-PET could identify relevant markers
to better predict the grading of gliomas.
Among advanced technics, Cho/Cr ratio presented interesting per-
formances for the discrimination of different grades. This was also
shown in our study, particularly between grade II and grade III gliomas
(p= 0.03). Indeed, Cho/Cr is well known to be correlated with tumor
cell proliferation (Herminghaus et al., 2002) and usually presents signif-
icant differences between low grade and high grade gliomas (Law et al.,
2003; Server et al., 2011; Yang et al., 2002; Zou et al., 2011). Our results
suggest that the use of Cho/Cr ratio could be of interest in the manage-
ment of grade II and grade III rather than [18F]-FLT PET, that did not
show signiﬁcant differences between these grades. rCBV has been
shown to be correlated with tumor aggressiveness and with grade in
enhancing and in non-enhancing lesions (Aronen et al., 1994; Lev
et al., 2004; Maia et al., 2005; Sadeghi et al., 2008; Shin et al., 2002;
Sugahara et al., 1998). rCBV has a better diagnostic performance in dif-
ferentiating between lowgrade andhigh grade gliomas than Cho/Cr andCho/NAA ratios obtained with MRS (Law et al., 2003), ADC (Arvinda
et al., 2009) or Ktrans (Law et al., 2004). While most studies compare
high grade and low grade, our study suggests that CBVmean and CBVmax
signiﬁcantly differ between patients with grade III and patients with
grade IV. For Zonari et al., rCBV is the most important parameter for ac-
curate tumor grading by differentiating grade II from III gliomas (Zonari
et al., 2007).
Along with [18F]-FDG, numerous other PET radiotracers have been
developed (for review, see (Dhermain et al., 2010; Wester, 2007))
to assess tumor aggressiveness such as 3′-[18F]ﬂuoro-3′-deoxy-L-
thymidine ([18F]-FLT) (Jacobs et al., 2005) or amino acid metabolism
by o-(2-[18F]ﬂuoroethyl)-L-tyrosine ([18F]-FET) (Hutterer et al., 2011)
or methyl-[11C]-L-methionine ([11C]-MET) (Derlon et al., 2000).
Among these tracers, [18F]-FLT correlates with cell proliferation, partic-
ularly in brain tumors (Chalkidou et al., 2012). This tracer has already
been used by us and others to assess grade (Ferdová et al., 2015), treat-
ment efﬁcacy (Corroyer-Dulmont et al., 2013; Schwarzenberg et al.,
2012) or prognosis (Idema et al., 2012). [18F]-FLT has also been assessed
and comparedwith other tracers as amarker for high grade gliomas and
probably more adapted for the grading compared to [11C]-MET or [18F]-
FET in this setting (Chen et al., 2005; Hatakeyama et al., 2008; Jacobs
et al., 2005; Jeong and Lim, 2012; Miyake et al., 2012). In agreement
with these reports, our study showed that [18F]-FLT parameters were
not sensitive enough to distinguish grade II from grade III gliomas, but
was the best parameter to distinguish grade IV from lower grade glio-
mas. Our results are in line of previouswork that already showed the in-
terest of using [18F]-FLT to differentiate low and high grade gliomas
(Yamamoto et al., 2012). We are also aware that PET imaging and
more precisely FLT PET are restricted, at the present time, to few hospi-
tal or research centers. In the present study, we propose that FLT PET
453S. Collet et al. / NeuroImage: Clinical 8 (2015) 448–454adds information in presence of suspicious patients where MRI may be
not sensitive enough before any treatment is decided but where biopsy
examination may lose some very aggressive “hot spot” thanks to the
great spatial heterogeneity.
Of note, we chose a static and delayed acquisition of [18F]-FLT images
since a dynamic acquisition (e.g. 2 h of acquisition) may not be realistic
for routine clinical practice. It has been shown that [18F]-FLT uptake oc-
curs due to increased transport through the blood–brain barrier (BBB)
and proliferation. When we focused on the condition for which the
[18F]-FLT tracer seemed to be relevant, i.e. the distinction between pa-
tients with grade III with CE and those with grade IV, all the tumors
had an alteration of the BBB.
Although the advanced MRI and PET parameters show more and
more interest and could become more accessible in the assessment of
glioma (Heiss et al., 2011; Puttick et al., 2015), studies have often
evaluated independently the interest of using either MRI or PET. In the
present study, we beneﬁt from the ability to compare the parameters
from both advanced MRI and PET for each patient and illustrate their
complementary role in glioma grading.
5. Conclusion
In conclusion, this study shows that [18F]-FLT could be of interest in
glioma classiﬁcation particularly in differentiating grade IV glioblastoma
from grade III or grade II gliomas. FLTmax seems to be the best parameter
to achieve this goal. Ourwork also illustrates the added value to acquire
both, advanced MRI and [18F]-FLT PET, to overcome the limitations of
conventional imaging for doubtful patients.
Conﬂicts of interest
The authors declare that they have no conﬂict of interest.
Funding
This study was funded by the Institut National contre le Cancer
(INCa), the Centre National de la Recherche Scientiﬁque (CNRS), the
Ministère de l3enseignement Supérieur et de la Recherche (MESR), the
Université de Caen Basse-Normandie (UCBN), the Conseil Régional de
Basse-Normandie (CRBN), the European Union — “Fonds Européen de
Développement Régional” (FEDER), l3Europe s3engage en Basse-
Normandie and the French National Agency for Research called
“Investissements d3avenir” no. ANR-11-LABEX-0018-01. These sponsors
were not involved in study design; in the collection, analysis and inter-
pretation of data; in thewriting of the report; and in the decision to sub-
mit the article for publication.
Acknowledgments
We thank neurosurgeons E. Emery, S. Khoury, B. Gadan, and
A. Borha. We also thank S. de Bouard, J. Pierre, S. Lecotcotigny and
A. Manrique. We thank Valerie Fong for editing the article.
References
Aronen, H.J., Gazit, I.E., Louis, D.N., Buchbinder, B.R., Pardo, F.S., Weisskoff, R.M., Harsh,
G.R., Cosgrove, G.R., Halpern, E.F., Hochberg, F.H., et al., 1994. Cerebral blood volume
maps of gliomas: comparison with tumor grade and histologic ﬁndings. Radiology
191 (1), 41–51. http://dx.doi.org/10.1148/radiology.191.1.81345968134596.
Arvinda, H.R., Kesavadas, C., Sarma, P.S., Thomas, B., Radhakrishnan, V.V., Gupta, A.K.,
Kapilamoorthy, T.R., Nair, S., 2009. Glioma grading: sensitivity, speciﬁcity, positive
and negative predictive values of diffusion and perfusion imaging. J. Neurooncol. 94
(1), 87–96. http://dx.doi.org/10.1007/s11060-009-9807-619229590.
Chalkidou, A., Landau, D.B., Odell, E.W., Cornelius, V.R., O3Doherty, M.J., Marsden, P.K.,
2012. Correlation between Ki-67 immunohistochemistry and 18F-ﬂuorothymidine
uptake in patients with cancer: a systematic review and meta-analysis. Eur.
J. Cancer 48 (18), 3499–3513. http://dx.doi.org/10.1016/j.ejca.2012.05.00122658807.Chen, W., Cloughesy, T., Kamdar, N., Satyamurthy, N., Bergsneider, M., Liau, L., Mischel, P.,
Czernin, J., Phelps, M.E., Silverman, D.H., 2005. Imaging proliferation in brain tumors
with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med. 46 (6), 945–95215937304.
Corroyer-Dulmont, A., Pérès, E.A., Petit, E., Guillamo, J.-S., Varoqueaux, N., Roussel, S.,
Toutain, J., Divoux, D., MacKenzie, E.T., Delamare, J., Ibazizène, M., Lecocq, M.,
Jacobs, A.H., Barré, L., Bernaudin, M., Valable, S., 2013. Detection of glioblastoma re-
sponse to temozolomide combinedwith bevacizumab based on μMRI and μPET imag-
ing reveals [18F]-ﬂuoro-L-thymidine as an early and robust predictive marker for
treatment efﬁcacy. Neuro-oncology 15 (1), 41–56. http://dx.doi.org/10.1093/
neuonc/nos26023115160.
Dean, B.L., Drayer, B.P., Bird, C.R., Flom, R.A., Hodak, J.A., Coons, S.W., Carey, R.G., 1990. Gli-
omas: classiﬁcation with MR imaging. Radiology 174 (2), 411–415. http://dx.doi.org/
10.1148/radiology.174.2.21533102153310.
Derlon, J.M., Chapon, F., Noël, M.H., Khouri, S., Benali, K., Petit-Taboué, M.C., Houtteville,
J.P., Chajari, M.H., Bouvard, G., 2000. Non-invasive grading of oligodendrogliomas:
correlation between in vivo metabolic pattern and histopathology. Eur. J. Nucl.
Med. 27 (7), 778–787. http://dx.doi.org/10.1007/s00259000026010952489.
Dhermain, F.G., Hau, P., Lanfermann, H., Jacobs, A.H., van den Bent, M.J., 2010. AdvancedMRI
and PET imaging for assessment of treatment response in patients with gliomas. Lancet
Neurol. 9 (9), 906–920. http://dx.doi.org/10.1016/S1474-4422(10)70181-220705518.
Ferdová, E., Ferda, J., Baxa, J., Tupý, R., Mraček, J., Topolčan, O., Hes, O., 2015. Assessment of
grading in newly-diagnosed glioma using 18F-ﬂuorothymidine PET/CT. Anticancer
Res. 35 (2), 955–95925667480.
Ginsberg, L.E., Fuller, G.N., Hashmi, M., Leeds, N.E., Schomer, D.F., 1998. The signiﬁcance of
lack of MR contrast enhancement of supratentorial brain tumors in adults: histopath-
ological evaluation of a series. Surg. Neurol. 49 (4), 436–440. http://dx.doi.org/10.
1016/S0090-3019(97)00360-19537664.
Hatakeyama, T., Kawai, N., Nishiyama, Y., Yamamoto, Y., Sasakawa, Y., Ichikawa, T.,
Tamiya, T., 2008. 11C-methionine (MET) and 18F-ﬂuorothymidine (FLT) PET in pa-
tients with newly diagnosed glioma. Eur. J. Nucl. Med. Mol. Imaging 35 (11),
2009–2017. http://dx.doi.org/10.1007/s00259-008-0847-518542957.
Heiss, W.-D., Raab, P., Lanfermann, H., 2011. Multimodality assessment of brain tumors
and tumor recurrence. J. Nucl. Med. 52 (10), 1585–1600. http://dx.doi.org/10.2967/
jnumed.110.08421021840931.
Herminghaus, S., Pilatus, U., Möller-Hartmann, W., Raab, P., Lanfermann, H., Schlote, W.,
Zanella, F.E., 2002. Increased choline levels coincide with enhanced proliferative ac-
tivity of human neuroepithelial brain tumors. N.M.R. Biomed. 15 (6), 385–392.
http://dx.doi.org/10.1002/nbm.79312357552.
Hilario, A., Ramos, A., Perez-Nuñez, A., Salvador, E., Millan, J.M., Lagares, A., Sepulveda,
J.M., Gonzalez-Leon, P., Hernandez-Lain, A., Ricoy, J.R., 2012. The added value of ap-
parent diffusion coefﬁcient to cerebral blood volume in the preoperative grading of
diffuse gliomas. A.J.N.R. Am. J. Neuroradiol. 33 (4), 701–707. http://dx.doi.org/10.
3174/ajnr.A284622207304.
Hutterer, M., Nowosielski, M., Putzer, D., Waitz, D., Tinkhauser, G., Kostron, H., Muigg, A.,
Virgolini, I.J., Staffen, W., Trinka, E., Gotwald, T., Jacobs, A.H., Stockhammer, G., 2011.
O-(2–18F-ﬂuoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in pa-
tients with recurrent high-grade glioma. J. Nucl. Med. 52 (6), 856–864. http://dx.doi.
org/10.2967/jnumed.110.08664521622893.
Idbaih, A., Ducray, F., Dehais, C., Courdy, C., Carpentier, C., de Bernard, S., Uro-Coste, E.,
Mokhtari, K., Jouvet, A., Honnorat, J., Chinot, O., Ramirez, C., Beauchesne, P.,
Benouaich-Amiel, A., Godard, J., Eimer, S., Parker, F., Lechapt-Zalcman, E., Colin, P.,
Loussouarn, D., Faillot, T., Dam-Hieu, P., Elouadhani-Hamdi, S., Bauchet, L., Langlois,
O., Le Guerinel, C., Fontaine, D., Vauleon, E., Menei, P., Fotso, M.J.M., Desenclos, C.,
Verrelle, P., Verelle, P., Ghiringhelli, F., Noel, G., Labrousse, F., Carpentier, A., Dhermain,
F., Delattre, J.-Y., Figarella-Branger, D., POLA Network, 2012. SNP array analysis re-
veals novel genomic abnormalities including copy neutral loss of heterozygosity in
anaplastic oligodendrogliomas. P.L.O.S. ONE 7 (10), e45950. http://dx.doi.org/10.
1371/journal.pone.004595023071531.
Idema, A.J.S., Hoffmann, A.L., Boogaarts, H.D., Troost, E.G.C., Wesseling, P., Heerschap, A., van
der Graaf,W.T.A., Grotenhuis, J.A., Oyen,W.J.G., 2012. 3′-Deoxy-3′-18F-ﬂuorothymidine
PET-derived proliferative volume predicts overall survival in high-grade glioma pa-
tients. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 53, 1904–1910. http://dx.doi.org/10.
2967/jnumed.112.105544.
Jacobs, A.H., Thomas, A., Kracht, L.W., Li, H., Dittmar, C., Garlip, G., Galldiks, N., Klein, J.C.,
Sobesky, J., Hilker, R., Vollmar, S., Herholz, K., Wienhard, K., Heiss, W.-D., 2005. 18F-
ﬂuoro-L-thymidine and 11C-methylmethionine as markers of increased transport
and proliferation in brain tumors. J. Nucl. Med. 46 (12), 1948–195816330557.
Jeong, S.Y., Lim, S.M., 2012. Comparison of 3′-deoxy-3′-[18F]ﬂuorothymidine PET and O-
(2-[18F]ﬂuoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl.
Med. Biol. 39, 977–981. http://dx.doi.org/10.1016/j.nucmedbio.2012.02.009.
Law, M., Yang, S., Babb, J.S., Knopp, E.A., Golﬁnos, J.G., Zagzag, D., Johnson, G., 2004. Com-
parison of cerebral blood volume and vascular permeability from dynamic suscepti-
bility contrast-enhanced perfusion MR imaging with glioma grade. A.J.N.R. Am.
J. Neuroradiol. 25 (5), 746–75515140713.
Law, M., Yang, S., Wang, H., Babb, J.S., Johnson, G., Cha, S., Knopp, E.A., Zagzag, D., 2003.
Glioma grading: sensitivity, speciﬁcity, and predictive values of perfusion MR imag-
ing and proton MR spectroscopic imaging compared with conventional MR imaging.
A.J.N.R. Am. J. Neuroradiol. 24 (10), 1989–199814625221.
Lev, M.H., Ozsunar, Y., Henson, J.W., Rasheed, A.A., Barest, G.D., Harsh, G.R., Fitzek, M.M.,
Chiocca, E.A., Rabinov, J.D., Csavoy, A.N., Rosen, B.R., Hochberg, F.H., Schaefer, P.W.,
Gonzalez, R.G., 2004. Glial tumor grading and outcome prediction using dynamic
spin-echo MR susceptibility mapping compared with conventional contrast-
enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas
[corrected]. A.J.N.R. Am. J. Neuroradiol. 25 (2), 214–22114970020.
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer,
B.W., Kleihues, P., 2007. The 2007 WHO classiﬁcation of tumours of the central
454 S. Collet et al. / NeuroImage: Clinical 8 (2015) 448–454nervous system. Acta Neuropathol. 114 (2), 97–109. http://dx.doi.org/10.1007/
s00401-007-0243-417618441.
Maia, A.C., Malheiros, S.M., da Rocha, A.J., da Silva, C.J., Gabbai, A.A., Ferraz, F.A., Stávale,
J.N., 2005. MR cerebral blood volume maps correlated with vascular endothelial
growth factor expression and tumor grade in nonenhancing gliomas. A.J.N.R. Am.
J. Neuroradiol. 26 (4), 777–78315814920.
Miyake, K., Shinomiya, A., Okada, M., Hatakeyama, T., Kawai, N., Tamiya, T., 2012. Usefulness
of FDG, MET and FLT-PET studies for the management of human gliomas. J. Biomed.
Biotechnol. 2012, 205818. http://dx.doi.org/10.1155/2012/20581822577290.
Puttick, S., Bell, C., Dowson, N., Rose, S., Fay, M., 2015. PET, MRI, and simultaneous PET/MRI
in the development of diagnostic and therapeutic strategies for glioma. Drug Discov.
Today 20 (3), 306–317. http://dx.doi.org/10.1016/j.drudis.2014.10.01625448762.
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., Delattre, J.-Y., 2012. Primary
brain tumours in adults. Lancet 379 (9830), 1984–1996. http://dx.doi.org/10.1016/
S0140-6736(11)61346-922510398.
Riemenschneider, M.J., Jeuken, J.W., Wesseling, P., Reifenberger, G., 2010. Molecular diag-
nostics of gliomas: state of the art. Acta Neuropathol. 120 (5), 567–584. http://dx.doi.
org/10.1007/s00401-010-0736-420714900.
Sadeghi, N., D3Haene, N., Decaestecker, C., Levivier, M., Metens, T., Maris, C., Wikler, D.,
Baleriaux, D., Salmon, I., Goldman, S., 2008. Apparent diffusion coefﬁcient and cere-
bral blood volume in brain gliomas: relation to tumor cell density and tumor
microvessel density based on stereotactic biopsies. A.J.N.R. Am. J. Neuroradiol. 29
(3), 476–482. http://dx.doi.org/10.3174/ajnr.A085118079184.
Schwarzenberg, J., Czernin, J., Cloughesy, T.F., Ellingson, B.M., Pope, W.B., Geist, C.,
Dahlbom, M., Silverman, D.H.S., Satyamurthy, N., Phelps, M.E., Chen, W., 2012. 3′-
Deoxy-3′-18F-ﬂuorothymidine PET and MRI for early survival predictions in patients
with recurrent malignant glioma treated with bevacizumab. J. Nucl. Med. Off. Publ.
Soc. Nucl. Med. 53, 29–36. http://dx.doi.org/10.2967/jnumed.111.092387.
Scott, J.N., Brasher, P.M., Sevick, R.J., Rewcastle, N.B., Forsyth, P.A., 2002. How often are
nonenhancing supratentorial gliomas malignant? A population study. Neurology 59
(6), 947–949. http://dx.doi.org/10.1212/WNL.59.6.94712297589.
Server, A., Kulle, B., Gadmar, Ø.B., Josefsen, R., Kumar, T., Nakstad, P.H., 2011. Measure-
ments of diagnostic examination performance using quantitative apparent diffusion
coefﬁcient and proton MR spectroscopic imaging in the preoperative evaluation oftumor grade in cerebral gliomas. Eur. J. Radiol. 80 (2), 462–470. http://dx.doi.org/
10.1016/j.ejrad.2010.07.01720708868.
Shin, J.H., Lee, H.K., Kwun, B.D., Kim, J.-S., Kang, W., Choi, C.G., Suh, D.C., 2002. Using rela-
tive cerebral blood ﬂow and volume to evaluate the histopathologic grade of cerebral
gliomas: preliminary results. A.J.R. Am. J. Roentgenol. 179 (3), 783–789. http://dx.doi.
org/10.2214/ajr.179.3.179078312185064.
Sugahara, T., Korogi, Y., Kochi, M., Ikushima, I., Hirai, T., Okuda, T., Shigematsu, Y., Liang, L.,
Ge, Y., Ushio, Y., Takahashi, M., 1998. Correlation of MR imaging-determined cerebral
blood volume maps with histologic and angiographic determination of vascularity of
gliomas. A.J.R. Am. J. Roentgenol. 171 (6), 1479–1486. http://dx.doi.org/10.2214/ajr.
171.6.98432749843274.
Van den Bent, M.J., 2010. Interobserver variation of the histopathological diagnosis in clin-
ical trials on glioma: a clinician3s perspective. Acta Neuropathol. 120 (3), 297–304.
http://dx.doi.org/10.1007/s00401-010-0725-720644945.
Wester, H.-J., 2007. Nuclear imaging probes: from bench to bedside. Clin. Cancer Res. 13
(12), 3470–3481. http://dx.doi.org/10.1158/1078-0432.CCR-07-026417575209.
Yamamoto, Y., Ono, Y., Aga, F., Kawai, N., Kudomi, N., Nishiyama, Y., 2012. Correlation of
18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients
with newly diagnosed and recurrent gliomas. J. Nucl. Med. 53 (12), 1911–1915.
http://dx.doi.org/10.2967/jnumed.112.10472923081994.
Yang, D., Korogi, Y., Sugahara, T., Kitajima, M., Shigematsu, Y., Liang, L., Ushio, Y.,
Takahashi, M., 2002. Cerebral gliomas: prospective comparison of multivoxel 2D
chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and
diffusion-weighted MRI. Neuroradiology 44 (8), 656–666. http://dx.doi.org/10.
1007/s00234-002-0816-912185543.
Zonari, P., Baraldi, P., Crisi, G., 2007. Multimodal MRI in the characterization of glial neo-
plasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and
echo-planar perfusion imaging. Neuroradiol. 49 (10), 795–803. http://dx.doi.org/10.
1007/s00234-007-0253-x17619871.
Zou, Q.-G., Xu, H.-B., Liu, F., Guo, W., Kong, X.-C., Wu, Y., 2011. In the assessment of
supratentorial glioma grade: the combined role of multivoxel proton MR spectrosco-
py and diffusion tensor imaging. Clin. Radiol. 66 (10), 953–960. http://dx.doi.org/10.
1016/j.crad.2011.05.00121663899.
